



Cost-Benefit Analysis – NRC Staff Guidance Updates

September 2017

Tina Ghosh and Amy Sharp
Office of Nuclear Regulatory Research



Background

- NRC performs cost-benefit analyses as part of:
 - Cost-justified substantial safety enhancements (i.e., backfit analyses)
 - Regulatory analyses
 - Environmental assessments
- MACCS provides inputs to cost-benefit calculations
 - Averted economic consequences
 - Averted dose



Background

- Fukushima Dai-ichi accident initiated questions regarding how NRC considers potential economic consequences (EC) of a nuclear accident
- SECY-12-0110, “Consideration of EC within the U.S. NRC’s Regulatory Framework”
 - SECY-14-0002, “Plan for Updating NRC’s Cost-Benefit Guidance”
 - SECY-14-0143, “Regulatory Gap Analysis of the NRC’s Cost-Benefit Guidance and Practices”



Two-Phased Approach

- Phase 1 – Administrative and methodology enhancements
 - Revise and restructure regulatory cost-benefit guidance documents
 - Refocus and expand guidance on cost-benefit analysis across the agency
 - Update data, methods, and references
- Phase 2 – Address potential changes in policy and methodology and maintain/update guidance
 - Process for addressing emergent policy issues identified by gap analysis
 - Revised guidance on Severe Accident Risk Analysis
 - MELCOR Accident Consequence Code System (MACCS)
 - Periodic review of cost-benefit guidance

NUREG-1530 Rev 1, “Reassessment of NRC’s Dollar per Person-Rem Conversion Factor Policy”



Dollar per Person-Rem

- NUREG-1530 Rev 1 “Reassessment of NRC’s Dollar per Person-Rem Conversion Factor Policy”
- This factor translates radiological dose “to a monetary value and, as such, allows for direct comparison between the potential health and safety benefits and the costs of a proposed regulatory initiative.”
 - 60 Federal Register 65694*

*<https://www.federalregister.gov/d/95-30888>



Background

- The NRC first used a dollar per person-rem value in 1974. The value set was \$1,000 per person-rem.
- This value was revisited, resulting in the publication of NUREG-1530 in 1995, which established a value of \$2,000 per person-rem and separated the offsite economic consequences from this factor.
- In 2009, the staff began research to update the dollar per person-rem value.
- SECY-12-0110 indicated that the staff would update guidance documents relating to cost-benefit analyses, including NUREG-1530. The Commission approved the staff's recommendation in 2013.



Calculating Dollar per Person-Rem

How is dollar per person-rem calculated?

- The NRC multiplies a current VSL by a cancer risk coefficient.
- NUREG-1530, published in 1995, uses a VSL of \$3 million and a cancer risk coefficient of 7.0×10^{-4} per person-rem from International Commission on Radiological Protection (ICRP) 60 published in 1991. This approximates a dollar per person-rem value of \$2,000.
- Currently, NUREG-1530 does not provide a method for adjusting this value into real dollars.



Proposed Changes to NUREG-1530

- Update the dollar per person-rem conversion factor from \$2,000 to \$5,200 per person-rem for the best estimate.
- Vary the dollar per person-rem conversion factor by plus or minus 50%, resulting in low and high values of \$2,600 and \$7,800 per person-rem, respectively.
- Report dollar per person-rem factor to two significant figures.
- Propose methods for maintaining the dollar per person-rem conversion factors.
- Provide guidance to staff on when to use the dose and dose-rate effectiveness factor (DDREF).



Value of a Statistical Life (VSL)

- VSL concept used widely throughout the Federal government to monetize the health benefits of a safety regulation.
- VSL is **NOT** a value placed on a human life, but a value that society would be willing to pay for reducing health risk.
- NRC utilizes the willingness-to-pay (WTP) method for calculating VSL, consistent with other Federal agencies.
- NRC used the research done by other Federal agencies in calculating VSL.
- The NRC staff applied a best estimate VSL calculation of \$9 million in 2014 dollars in NUREG-1530, Revision 1.
 - This estimate is derived from the average of the Department of Transportation's (DOT's) VSL (\$9.3 million) and the Environmental Protection Agency's (EPA's) VSL (\$8.7 million) in 2014 dollars.



Basis for VSL Sensitivity Analysis

- The NRC has adopted the EPA practice to use a central VSL estimate without a probability distribution.
- This practice is consistent other Federal agencies practices in the use of VSL, notably:
 - EPA guidance states, “Until updated guidance is available, the Agency determined that a single, peer-reviewed estimate applied consistently best reflects the SAB-EEAC advice received to date.”
 - DOT guidance prescribes “a sensitivity analysis of the effects of using alternative VSL values. Instead of treating alternatives values in terms of a probability distribution, analysts should apply only a test of low and high alternative values...”.



Cancer Risk Coefficient

- NUREG-1530 (1995) uses the total cancer risk coefficient value from ICRP 60, published in 1991, of 7.0×10^{-4} per person-rem.
- ICRP 103 (2007) presents an updated cancer risk coefficient of 5.7×10^{-4} per person-rem.
- In 2011, the EPA published a cancer mortality-only risk coefficient of 5.8×10^{-4} per rem
- Based on public comments received, the staff selected the EPA's cancer mortality risk coefficient.



Dose and Dose Rate Effectiveness Factor (DDREF)

- Intrinsic to the EPA cancer mortality risk coefficient is a judgment that the per person-rem health detriment below certain doses and dose rates would be lower by a factor of 1.5, compared to the higher dose and dose rates where human health effects have been observed.
- This factor is called the DDREF and is included in the EPA cancer mortality risk coefficient and the NRC staff's proposed dollar per person-rem conversion factor.
- This factor would be removed for special cases involving high dose or high dose rates.

NUREG/BR-0058 Rev 5, “U.S.
NRC Regulatory and Cost-Benefit
Analysis Guidance”



NUREG/BR-0058 Update

- Refocuses and expands guidance on cost-benefit analysis across the agency.
- Focuses on quantification and methods for creating realistic estimates.
- Provides methods for assessing factors that are difficult to quantify.
- Incorporation of cost estimating best practices.
- Expands on the treatment of uncertainties.
- Enhances transparency of analysis for the decisionmaker.



Regulatory Analysis

- A formal, highly-structured, reasoned analysis of a proposed government agency requirement containing estimates of costs and benefits that are quantified to the fullest extent possible
- Includes societal cost-benefit analysis
- An analytical tool provided to decisionmakers
 - Rationale for action
 - Enhances transparency of analyses
 - Consistency with Executive Orders on regulatory analysis and related issues
 - Compliance with Office of Management and Budget guidance and Executive Orders



Attributes Considered in Regulatory and Cost- Benefit Analyses

- Public Health (Accident)
- Public Health (Routine)
- Occupational Health (Accident)
- Occupational Health (Routine)
- Offsite Property
- Onsite Property
- Industry Implementation
- Industry Operation
- NRC Implementation
- NRC Operation
- Other Government
- General Population
- Improvements in Knowledge
- Regulatory Efficiency
- Safeguards and Security Considerations
- Environmental Considerations
- Other Considerations



Phase 2 Appendices

- Data Sources
- Historical Data
- Severe Accident Risk Analysis
- NEPA Cost-Benefit Analysis
- Morbidity
- Replacement Power Costs



Appendix H: Severe Accident Risk Analysis



Purpose

- PRAs and consequence analyses conducted to evaluate
 - Safety goal screening
 - Public health (accident) attribute
 - Economic consequences (offsite property) attribute
- Guidance and best practices recommended for use at the NRC in performing PRAs and consequence analyses as part of regulatory and backfit analyses
- Provides sources of information and an overview of the tools and methods used to estimate changes in core damage frequency, public health risk, and offsite economic consequences risk



Background

- NRC formally endorsed the use of PRA methods in 1995
 - “The use of PRA technology should be increased in all regulatory matters to the extent supported by the state-of-the-art in PRA methods and data”
 - This policy statement introduced the concept of risk-informed regulation and solidified the role of PRA methods and results in regulatory decisionmaking.
- The accident at Fukushima initiated a number of major regulatory analyses using state-of-the-art PRA and severe accident consequence analysis approaches
 - Filtered vents analysis, SECY-12-0157
 - Containment protection release reduction for Mark I and II containments, SECY-15-0085
 - Spent fuel pool study supporting evaluation of expedited transfer or spent fuel, SECY-13-0112 and COMSECY-13-0030
 - Mitigation of beyond-design basis events, SECY-15-0085



Contents

- PRA Model Selection Guidance
- Risk Metrics for Substantial Safety Benefit Evaluation
- Accident Sequence Analysis
- Severe Accident Progression Analysis
- Offsite Consequence Analysis
- Sensitivity and Uncertainty Analysis



Off-site Consequence Analysis

- Sources of information
 - “Technical Bases for Consequence Analyses using the MELCOR Accident Consequence Code System” NUREG under development
- Source term characterization
- Site and Meteorological Data
- Protective Actions Modeling



MACCS Updates

- Commission Staff Requirements Memorandum (SRM) to SECY-12-0110 emphasized that “improving guidance and analysis tools (such as the MACCS2 computer code) based on up-to-date data and advancements in accident consequence assessment knowledge” should be a priority
- New ATD Model (HYSPLIT) Integration
- Alternative Economic Consequences Model



References

- U.S. NRC, “Use of Probabilistic Risk Assessment Methods in Nuclear Regulatory Activities; Final Policy Statement.” available at <https://www.federalregister.gov/d/95-20237>
- ICRP, 1991. 1990 Recommendations of the International Commission on Radiological Protection. ICRP Publication 60. Ann. ICRP 21 (1-3)
- ICRP, 2007. The 2007 Recommendations of the International Commission on Radiological Protection. ICRP Publication 103. Ann. ICRP 37 (2-4)
- NUREG/BR-0058, Rev. 4 available in ADAMS at ML042820192
- NUREG/BR-0058, Rev. 5 available in ADAMS at ML17023A180
- NUREG-1530 available at ML063470485
- NUREG-1530, Rev. 1 available at ML17018A239
- SECYs
 - available at <http://www.nrc.gov/reading-rm/doc-collections/commission/> or in ADAMS
 - SECY-12-0110 available at ML12173A478
 - SECY-14-0002 available at ML13274A519
 - SECY-14-0143 available at ML14280A426
 - SRM-SECY-12-0110 available at ML13079A055